Splicing mutations account for ~10% of lesions causing genetic diseases, but few branchpoint sequence (BPS) lesions have been reported. In three families with autosomal recessive congenital erythropoietic porphyria (CEP) due to uroporphyrinogen III synthase (URO-synthase) deficiency, sequencing the promoter, all 10 exons and the intron/exon boundaries did not detect a mutation. Northern analyses of lymphoblast mRNAs from two patients and RT/PCR of lymphoblast mRNAs from all three patients revealed multiple longer transcripts involving intron 9 and low levels of wild-type message. Sequencing intron 9 RT/PCR products and genomic DNA in each case revealed homozygosity for a novel BPS mutation (c.661-31T>G) and alternatively-spliced transcripts containing 81, 246, 358, and 523 nucleotides (nt) from intron 9.
INTRODUCTION
Congenital erythropoietic porphyria (CEP) is an autosomal recessive inborn error of heme biosynthesis resulting from markedly deficient, but not absent, activity of the fourth enzyme in the heme biosynthetic pathway, uroporphyrinogen III synthase (URO-synthase; EC 4.2.1.75) 1 .
This enzyme catalyzes the conversion of the linear tetrapyrrole, hydroxymethylbilane, to uroporphyrinogen (URO'gen) III, the only isomer of URO'gen that can ultimately be converted to heme 2, 3 . Deficient activity of URO-synthase in CEP patients results in the non-enzymatic cyclization of hydroxymethylbilane to URO'gen I. An excess of URO'gen I and COPRO'gen I
and their oxidized forms, uroporphyrin (URO) I and coproporphyrin (COPRO) I, primarily in erythrocytes, leads to hemolysis. The released porphyrins accumulate in tissues and bones and are excreted in the urine and feces. Light activates the photocatalytic URO I and COPRO I isomers, resulting in tissue damage and the formation of bullous cutaneous lesions which rupture, often becoming infected, and lead to bone resorption and cutaneous deformity 4 .
The clinical manifestations of CEP are markedly heterogeneous, dependant primarily on the amount of residual URO-synthase activity, and range from non-immune hydrops fetalis to milder, later-onset forms 1, 4 . Severely affected patients are transfusion-dependent throughout life, have splenomegaly, and marked cutaneous involvement leading to severe scarring and/or deformities. Additional manifestations may include hypertrichosis, alopecia, and erythrodontia.
Patients with a milder phenotype, who have sufficient residual URO-synthase activity to synthesize heme for hemoglobin and other essential heme-requiring proteins, are not transfusiondependent and may only exhibit cutaneous involvement.
The ~34 kb human URO-synthase gene, located at chromosome 10q25.3-26.3, has 10 exons and two alternative promoters that generate housekeeping-and erythroid-specific transcripts 5 that express the same enzyme polypeptide of 265 amino acids (molecular mass ~29.5 kD). To date, 38 mutations have been identified in unrelated CEP patients (Human Gene Mutation Database; http://www.hgmd.cf.ac.uk/). These include 24 missense mutations, one nonsense, two
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From 4 splice site (c.63+1G>A; c.245-2A>T), two deletions, four insertions and one complex rearrangement. Only the C73R missense mutation is common, occurring in about one third of the CEP alleles studied, whereas the other mutations have been detected in only one to three presumably unrelated families 4, 6 . Most of the missense mutations expressed in E. coli had low activity (<2% of wild-type), but several were found to have significant residual activity which appeared to correlate with the milder, later-onset phenotypes 4 .
Disease-causing point mutations in the branchpoint consensus sequence (BPS) are rare. To date, 17 BPS mutations causing human disease have been described (Data Supplement, Table   1S ). Of the 17, all but two are either mutations of the consensus branching adenosine or the -2 thymidine (consensus BPS = YNYTRAY). Both exon skipping, intron retention, partial intron retention due to activation of cryptic 3'-splice sites, and combinations of these events have been observed which presumably depends on the particular sequence context in each gene. Here, we report a novel branchpoint mutation in the last intron of the URO-synthase gene in three CEP patients that resulted in at least a 90% reduction of the wild-type 1.5 kb message. Multiple alternatively-spliced mRNAs were detected, ranging in size from 1.6 to 2.0 kb. Characterization and quantitation of the alternatively-spliced mRNAs revealed that they were present in both normal and patient cells and resulted from retention of intronic sequences due to the use of cryptic splice sites in intron 9. There was no evidence of exon skipping. Of the alternativelyspliced transcripts, only the +81 nt in-frame insertion transcript encoded an active enzyme that, when pure, expressed ~4% of wild-type prokaryotically-expressed enzymatic activity and when in crude extracts expressed 0.6% of wild-type activity. Thus, the branchpoint mutation caused a marked reduction of the normal transcript and encoded enzyme, thereby causing the disease in these patients.
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MATERIALS AND METHODS
Patients
Peripheral blood samples were collected at The Mount Sinai School of Medicine in New York with informed consent from 9 unrelated CEP patients and their family members. All studies involving patient samples were performed with approval from the Mount Sinai institutional review board in accordance with the Declaration of Helsinki. Lymphoid cell lines were established as previously described 7 . Patients 3 and 6, were 15-and 20-year-old white males of Ashkenazi descent. Their parents were not related to each other. Patient 3 was severely affected from birth with marked photosensitivity, hepatosplenomegaly, and anemia (hemoglobin 5 g/dL at 20 days of life 8 ). He was treated with red cell transfusions until age 14, when worsening photosensitivity was managed with continued chronic hemotransfusions and marrow suppression with hydroxyurea 9 . Patient 6 required red cell transfusions, but had significant periods during adolescence without treatment. He had marked cutaneous involvement resulting from unprotected exposure to sunlight.
Patient 10, studied in Zurich, was a 44-year-old male of Lebanese descent, who was the product of consanguineous parents 10 . He had suffered from chronic, progressive skin ulcerations since adolescence that eventually disfigured his sun-exposed face and hands. CEP was recognized when he was in his 20s. Following his initial evaluation, he remained moderately anemic with hemoglobins ranging from 10 to 12 g/dL over the next decade. At age 56, his hemoglobin was 8 g/dL and red cell transfusions were administered every three weeks.
The clinical diagnosis of CEP was confirmed in Patients 3, 6, and 10 by finding markedly elevated levels of URO I in the urine. Erythrocyte URO-synthase activities could not be determined, as all patients were receiving transfusions of normal erythrocytes.
Initial molecular studies of Patients 3 and 6 in New York included Northern, Southern, and allele-specific hybridization analyses, followed by the identification and characterization of the First strand cDNA was reverse-transcribed from 1 μg of poly(A) + RNA using the AMV Reverse Transcriptase System (Gibco Invitrogen, Carlsbad, CA, USA) and primer AS1, AS2, or AS3 (Data Supplement, Table 2S ). The cDNA template (1 µg; 10% of the reaction) was PCRamplified for 30 cycles. Primer set 1, located in exons 1 and 8, amplified the 5' half of the cDNA; primer set 2, located in exon 7 and in the 3' UTR of exon 10 amplified the 3' half of the cDNA; and primer set 3, located in exons 9 and 10 amplified intron 9 (See Data Supplement, Table 2S ). The amplicons were analyzed by electrophoresis in 1.5% agarose gels.
The PCR products were digested with Eco RI, gel purified and ligated into the Eco RI site of the pGEM4Z vector (Promega, Madison, WI, USA). Clones corresponding to the observed agarose gel bands were sequenced using an ABI 3730xl capillary array sequencer (Applied Biosystems, Foster City, CA, USA) to determine the identity of the alternatively-spliced transcripts. 
Quantitative RT/PCR Analyses.
For quantitative RT/PCR of the URO-synthase wild-type and alternatively-spliced transcripts from Patients 3 and 6, total RNA was isolated from cultured lymphoblasts using TRI-Reagent ® (Ambion, Austin, TX, USA). Real-time PCR was performed using TaqMan Universal PCR 2X
MasterMix and the SYBR Green PCR core reagents, both from Applied Biosystems, Foster City, CA. The primers used are specified in Data Supplement, Table 2S . Quantitation was performed on an ABI PRISM 7900HT (Applied Biosystems) normalized to the average of the GAPDH, α-actin, β-tubulin and rps11 transcript levels. The cycle threshold (Ct) values were determined in triplicate for two to three RNA samples from each individual. Relative quantitation and propagation of error calculations were carried out as described 11 . The calibrator was the mean wild-type transcript level in normal controls, and the amounts of each transcript were expressed as a percentage of the total wild-type and alternatively-spliced transcripts in normal individuals.
Similarly, for quantitation of wild-type and Patient 10's abnormal transcripts, total RNA was Table 2S ) were used to quantify the URO-synthase cDNA by real-time PCR ABI PRISM 7000 (Applied Biosystems). Quantitation was normalized relative to the average of the 18S and β-actin RNAs.
Computer-Assisted Analyses.
DNA sequence analyses were performed using the MacVector 9 DNA sequence analysis program (MacVector Inc, Cary, NC, USA). Exon splice enhancers (ESEs) were identified using the ESEfinder3 program:
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) 12, 13 . The thresholds for significant SF2/ASF and SC35 scores were set at (http://www.cbs.dtu.dk/services/NetGene2/) 14 . The program's reported 5'-donor and 3-acceptor "Confidence Scores" were used as a measure of splicing potential and termed "Splice Scores" in the text. Of note, the 81 bp intronic region common to all of the alternatively-spliced transcripts was predicted to be an exon using the GENESCAN program 15 , indicating that this region was suitable for splicing. Putative cryptic exons and their associated splice site scores, obtained using the NetGene2 program 16 , the associated BPS and polypyrimidine sequences, and their 5' and 3'
splice scores are shown in Table 1 .
Prokaryotic Expression, Thermostability and Enzyme Assay.
The novel 27 in-frame residues encoded by the +81 nt alternatively-spliced transcript were introduced by site-directed mutagenesis into pKK. The wild-type URO-synthase prokaryotic expression construct and the crude extracts were assayed for URO-synthase enzymatic activity as previously described 17 . These constructs were also cloned into a high-level pET SUMO expression vector as a SUMO fusion protein, cleaved and purified to homogeneity as previously described 18 . The pure wild-type and mutant enzymes were incubated in 20 mM HEPES, pH 7.4, 0.1 M NaCl, and 1 mM dithiothreitol, for various times at 37°C, transferred to an ice bath and then assayed as above to determine thermostability.
RESULTS
Detection and Characterization of Abnormal mRNAs.
Among the 10 clinically diagnosed CEP patients with markedly elevated urinary URO I and COPRO I levels, including Patients 3 and 6 in New York, and subsequently, Patient 10 in Zurich, sequencing of the URO-synthase exons, adjacent intron/exon boundaries, and promoter regions did not identify causative mutations. To screen for mRNA processing errors, lymphoblast poly(A) + RNAs were analyzed from CEP Patients 1 through 9 by Northern hybridization using the full-length URO-synthase cDNA as a probe. As shown in Figure 1 ,
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Patients 3 and 6 had markedly reduced amounts of the wild-type 1.5 kb transcript and readily observable amounts of several larger mRNA species with hybridization bands of approximately 1.6, 1.8 and 2.0 kb, while the other CEP patients and a normal control had a single UROsynthase mRNA band of ~1.5 to 1.6 kb.
To determine the nature of the longer transcripts in Patients 3 and 6, mRNAs isolated from cultured lymphoblasts were reverse-transcribed and exons 1 through 8 and 7 through 10 were amplified using primer sets 1 and 2, respectively (Data Supplement, Table 2S ). In these CEP patients, PCR amplification from exons 1 through 8 generated only one amplicon of expected size, whereas amplification of exons 7 through 10 revealed longer amplicons in Patients 3 and 6 and to a lesser degree, in their parents (Figure 2 ). In the parents of Patients 3 and 6, RT/PCR of URO-synthase exons 9 through 10 (primer set 3; Data Supplement, Table 2S ), generated predominantly the normal-sized 155 bp product as well as smaller quantities of some of the longer amplicons seen in Patients 3 and 6 (Fig. 2) , while the normal control cDNA had primarily (Figs. 2 & 3) . In all cases, except for the in-frame 27 amino acid insertion, the variant proteins lacked the 45 amino acid terminal region of URO-synthase encoded by exon 10.
Expression, Thermostability, and Enzymatic Activity of the Variant Enzyme.
The additional 27 amino acid peptide of the URO-synthase variant protein encoded by the +81 nt in-frame insertion transcript was located far from the active site, so to determine if it had any residual enzyme activity the +81 bp insertion transcript was prokaryotically expressed and compared with the wild-type construct, the pKK vector alone, and a previously reported CEP missense mutation (p.Ala69Thr) as a control. As shown in Table 2 , in crude extracts, the +27 amino acid mutant protein had 0.6% of the expressed wild-type activity, whereas the p.A69T missense mutation had a residual activity similar to that previously reported, 1.4% of expressed wild-type activity 19 . In addition, the +27 amino acid mutant protein was expressed from the pET SUMO construct, purified to homogeneity, and shown to have only 4.2% of wild-type expressed activity ( Table 2 ). The pure wild-type and mutant enzymes were both stable at pH 7.4 and 37°C for 1 hr. In contrast, the other frame-shifted alternatively-spliced transcripts all predicted the incorporation of different amino acids, with premature termination which deleted the terminal 45 amino acids encoded by exon 10. Confirmation of the c.661-31T>G mutation was made in Patients 3 and 6 and their parents by demonstrating the presence of the lesion in genomic DNAs from each by dot-blot hybridization with allele-specific oligonucleotides (data not shown). Amplified genomic DNAs from these patients hybridized strongly with the mutation-specific ASO, confirming that the patients were homoallelic for the base substitution. Genomic DNAs from each of their parents were heterozygous, hybridizing with both the normal and mutation-specific oligonucleotides.
To evaluate the possibility that the T to G substitution represented a polymorphism, genomic DNAs from 50 unrelated Ashkenazi Jewish normal individuals were PCR-amplified and screened for the c.661-31T>G mutation by dot-blot analysis with the ASOs. None of the 100 wild-type alleles tested positive for this base substitution, suggesting that the base change was not a common polymorphism (data not shown).
In Vivo Abundance of the Wild-Type and Alternatively-Spliced mRNAs.
To assess the relative amounts of the normal and alternatively-spliced transcripts in these three CEP patients, quantitative real-time PCR primers and TaqMan probes were designed (Data Supplement, Table 2S ) to specifically analyze each splice variant (Fig. 3B) . The results (Table 3) indicated that the normal 1.5 kb transcript accounted for ~81% of the total transcript mRNA, while the major alternatively-spliced transcripts, corresponding to retention of intronic sequences of 81 bp, 81+165 bp, and 81+277 bp, represented 14, 5 and 0.3%, respectively, of the total transcript mRNA in normal individuals. The mean percentage of wild-type 1.5 kb transcript in For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 13 the lymphoblasts of all three patients was ~10% of that in normal lymphoblasts, while the mean levels of the alternatively-spliced transcripts were similar or slightly higher than those in the normal controls. Note that of the five independent replicate assays for the percentage of normal transcripts in the three CEP patients, four were 5% (all three patients) with one outlier of 33% Table 3 ). This supports our observation that similar amounts of alternative transcripts were found in normal and CEP patients.
URO-Synthase Activities in Normal and Patient Lymphoblasts.
The mean URO-synthase activity in cytoplasmic extracts of normal lymphoblasts was 7.36 ± 0.07 (StdDev) units/mg protein. For Patients 3 and 6, their residual activities were 14.1% and 14.8%, respectively, an average residual activity of 14.4 ±0.5% of wild-type activity.
Characterization of the Intron 9 Cryptic Splice Sites.
As shown in Figure 3 
In Silico Prediction of Splice Site Utilization.
To evaluate the potential for the alternative splicing that resulted in intron 9 retention in normal individuals and CEP patients, in silico analyses were performed to assess splice site favorability by identifying juxtaposed cryptic BPSs and pyrimidine tracts. The highest 5' splice site score (0.94) was for the authentic exon 10 with the next highest scores associated with cryptic exons CE4 (0.69) and CE5 (0.64) that were the intronic sequences retained in the alternatively-spliced transcripts that had the additional 165 and 81 bp intronic sequences, respectively (Fig. 3 and Data Supplement, Figure 1S ). These two cryptic exons also had the highest 3' splice scores (both were 0.95; Table 1 ). For comparison, the 5' splice scores for normal exons 7, 8, 9, and 10 were 0.33, 0.43, 0.56 and 0.94, respectively. Thus, the presence of the alternatively-spliced transcripts in normal individuals and CEP patients was consistent with the favorable cryptic splice sites in intron 9.
The density of ESEs, splicing factor 2/alternative splicing factor (SF2/ASF), and SC35 were calculated (Table 1 ) and plotted along with the NetGene2 results (Data Supplement, Fig. 1S ).
ESE motifs SRp20, SRp40, and SRp55 were relatively uniform in distribution throughout intron 9 and thus were not informative. There were 3 to 10 times more SC35 and SF2/ASF motif ESE sites in exon 10 and in the retained intron 9 cryptic exons CE4 and CE5 than in the proximal 2.7 kb (CE1 and CE2) of intron 9 (Table 1 and Data Supplement Fig. 1S ). The frequency of SC35 abd SF2/ASF motifs in CE4 and CE5 were 28.5 and 37 per kb, respectively, while in comparison, the frequency of the SC35 motif in 2,626 exons and 2,079 introns revealed an average of 5.9/kb in introns versus 9.0 /kb in exons, a 1.5-fold difference that was statistically significant 20 . Thus, the cryptic exon use seen in both wild-type and the CEP c.661-31T>G
transcripts was consistent with the presence in the intron 9 sequence of high-propensity cryptic BPS sites, polypyrimidine tracts, splice junctions and ESE sites.
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DISCUSSION
Northern hybridization and RT/PCR analyses revealed molecular defects in the URO-synthase transcripts causing CEP in three unrelated patients in whom no mutations were found in the promoter, exons, and intron/exon boundaries in the URO-synthase gene. Subsequent sequence analysis identified the transversion c.661-31T>G in the intron 9 BPS in all three patients. That this BPS base change was the primary disease-causing mechanism was supported by: 1) its location at a highly conserved position in the BPS, -2 nt from the lariat-forming adenosine where base changes have previously altered interactions with the branchpoint-binding protein SF1 and with U2 snRNP (see below), 2) the absence of any other URO-synthase mutations that could account for the observed splicing defect, 3) the exclusion of the base change as a polymorphism in normal individuals, 4) the fact that the in-frame +27 amino acid variant encoded by the +81 nt alternative transcript had little activity, and 5) the mutation's segregation with disease in three CEP families who claimed to be unrelated. However, the presence of the same mutation for a very rare disease in the two Ashkenazi Jewish families and a third Semitic family suggests that the Jewish families may be related, that they may share a possible common Middle Eastern ancestor, or, and much less likely, that independent mutation events occurred. Analysis of 100 Ashkenazi Jewish alleles did not identify a base substitution, indicating a frequency less than 1%.
With the exception of the in-frame +81 nt alternatively-spliced transcript, each of the other splicing variants in these patients would result in frame-shifted, non-functional, and prematurely terminated URO-synthase mutant polypeptides lacking the terminal 45 amino acids encoded by exon 10. Exon 10 is the site of at least six known CEP mutations highlighting its functional importance. It is unlikely that an enzyme resulting from any of these aberrant transcripts that encoded novel peptides and/or deleted exon 10 would be active based on structural mapping studies.
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Prokaryotic expression of the in-frame +81 nt insertion transcript resulted in 4.2% of expressed wild-type activity for the pure enzymes and 0.6% of wild-type URO-synthase enzymatic activity in crude extracts ( Table 2 ). The lower yield in crude extracts was possibly due to proteolytic instability, since the mutant enzyme was not thermolabile. Since the average abundance of this transcript in lymphoblasts ranged from 12 to 27% of the normal transcript (Table 3) , the low activity of the mutant expressed protein indicated that its contribution to residual activity would be only 0.2% to 1% (0.6% or 4.2% x 27%), a negligible contribution compared to the 14% residual enzyme activity observed in patient lymphoblasts due to the presence of normal transcript. Differences in tissue-specific expression could result in the residual activity being lower in erythroid cells due to message and/or enzyme instability.
However, this level of residual activity is comparable to previous reports of 4-33% residual activity, mean=16%, in early onset CEP patients (eg. Freesemann, et al. 21 ). Thus, these studies demonstrate that the disease-causing mechanism in these patients is the -2 BPS mutation which markedly decreased the amount of the wild-type transcript, and hence, reduced the amount of normal URO-synthase.
The role of the BPS in the splicing of hnRNAs has been the subject of intense investigation (for reviews, see [22] [23] [24] [25] [26] [27] [28] [29] . NMR spectroscopy 30 showed that the -2 uridine exhibits specific contacts with at least 6 residues in human SF1. The critical role of the -2 position also has been confirmed by functional studies and observed mutation frequencies; the most highly conserved positions are 0 and -2 31, 32 . The lariat adenosine and the -2 T are also the most critical bases in vivo since their alteration accounts for 16 out of the 18 human disease-causing BPS mutations (Data Supplement, Table 1S ). Thus, the observed decreased wild-type transcript in the CEP patients, along with the presence of larger transcripts using alternative BPSs and splicing sites might be expected, as inhibiting the binding of SF1 blocks the subsequent binding of the U2 snRNP 33 .
There was no evidence of exon skipping in association with this mutated BPS in the last intron of URO-synthase. This contrasts with the previously published four -2 BPS mutations (for Table 1S ). It is interesting that no cryptic splice sites were available anywhere beyond the last intron. Exon skipping due to BPS mutations in the last intron may be selected against by elimination of potential exons in the 3' untranslated region and beyond.
In summary, these studies demonstrated the occurrence of alternative splicing of the UROsynthase transcript in normal individuals and CEP patients, consistent with the presence of additional splice sites and ESE sites in intron 9 that generated these minor normally-occurring alternative transcripts. Of these alternatively-spliced transcripts, only the +81 nt in-frame insertion transcript encoded a viable enzyme protein, albeit contributing to only about 0.2% of wild-type activity. Thus, the BPS mutation markedly reduced the amount of wild-type UROsynthase transcript, thereby causing CEP in these patients. Table 2S .
